Pharmacokinetic study on biapenem
Keywords:
Biapenem
1994 Volume 42 Issue Supplement4 Pages 277-284
Details
1994 Volume 42 Issue Supplement4 Pages 277-284
We studied the pharmacokinetics of biapenem (BIPM), a new carbapenem antibiotic, and compared to imipenem/cilastatin (IPM/CS) by cross-over method.
300mg of BIPM and 500mg/500mg of IPM/CS administered to six healthy volunteers by intravenous drip infusion, and the plasma and urine concentration were measured.
After 30 minutes infusion, the maximum plasma concentration (Cmax) of BIPM was 18.9±3.0μg/ml and IPM/CS was 31.4±6.5μg/ml, and the area under the curve (AUC) were 27.17±3.82μg·h/ml and 41.74±8.84μg·Eh/ml.
The plasma half-life beta phase (T1/2β) were 1.07±0.15hr and 0.89±0.07hr, renal clearance were 6.90±0.95l/h and 8.07±1.07l/h, total clearance were 11.23±1.58l/h and 12.45±2.72g/h, the urine excretion rate up to 12 hours were 61.5% and 66.2%, these parameter of BIPM was nearly same as that of IPM/CS. The metabolite of BIPM urine was detected by high performance liquid chromatography (HPLC), 9.2% of LJC 10, 905 and 10.2% of LJC 10, 906. Total urine excretion rate, metabolites and unchanged BIPM was 80.9%.
These results suggest that the pharmacokinetics and stability of BIPM was nearly the same as that of IPM/CS.
No side effects or abnormal laboratory findings were observed in this examination.
